Skip to main content
    F

    FibroBiologics, Inc. Common Stock (FBLG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.00
    +0.05 (+5.26%)

    Market Cap: $6.73M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(7/9)
    Avg Surprise
    +33.07%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.63 - $-0.63
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.77+18.2%
    60d ago$-0.94+33.0%
    30d ago$-0.94+33.0%
    7d ago$-0.94+33.0%
    Current$-0.63
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.63---
    Jun 26
    Reported Jul 31
    		$-0.66$-0.93+29.03%Beat-450.0%
    Mar 26
    Reported Apr 30
    		$-1.33$-1.35+1.84%Beat+52.5%
    Dec 25
    Reported Feb 24
    		$-0.60N/A+70.00%Beat-566.7%
    Sep 25
    Reported Oct 31
    		$-2.60$-2.30-13.04%Miss-1200.0%
    Jun 25
    Reported Jul 31
    		$-0.12$-0.12+0.00%Beat-120.0%
    Mar 25
    Reported May 14
    		$-2.80$-2.50-12.00%Miss-937.0%
    Dec 24
    Reported Mar 27
    		$-0.09$-0.09+0.00%Beat-
    Sep 24
    Reported Nov 12
    		$-0.20N/A+88.44%Beat-
    Jun 24
    Reported Aug 7
    		$0.60N/A+133.33%Beat-
    Mar 24
    Reported May 14
    		$-0.27N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.19EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-660.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.64xQuick Ratio2.64x
    Trading Statistics
    Beta1.74Avg Volume140.61K
    52-Week High$9.6052-Week Low$0.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.08
    SMA 20$1.21
    SMA 50$1.34
    SMA 200$2.65
    EMA 10$1.08
    EMA 20$1.18
    EMA 50$1.25
    EMA 200$3.13

    MACD

    Line: -0.11Signal: -0.08Hist: -0.03

    ADX

    ADX: 25.0+DI: 14.8-DI: 27.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$1.17

    Bollinger Bands

    Upper Band$1.52
    Lower Band$0.91
    %B Position5057%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    34.0

    Momentum Oscillators

    Stoch %K7.7
    Stoch %D6.7
    Williams %R-86.4
    ROC (10d)-17.0%
    Momentum-0.20
    CCI (20d)-110.8
    MFI (14d)32.8

    Volatility Measures

    ATR (14d)$0.13(12.6%)
    StdDev (20d)0.15
    Hist Vol62.0%(High)

    Volume Flow

    VWAP$1.00
    OBV-41.5M
    AD Line87.4B
    CMF (20d)-0.375

    Volume Metrics

    Avg Vol (20d)143.6K
    Vol Ratio1.1x
    VWMA (20d)$1.22

    Pivot Points

    R3$1.10
    R2$1.06
    R1$1.00
    Pivot Point$0.96
    S1$0.91
    S2$0.87
    S3$0.81

    Advanced Oscillators

    TSI-27.16
    Ultimate Osc35.3
    KST-218.36

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$554,000$0$0$0$0$0
    Cost of RevenueN/AN/A$234,000$231,000$206,000N/A$153,000N/A$140,000$137,000$130,000$112,000
    Gross ProfitN/AN/A$-234,000$-231,000$-206,000N/A$277,000N/A$-140,000$-137,000$-130,000$-112,000
    Operating Expenses$4.03M$5.07M$2.36M$5.04M$4.49M$4.53M$3.71M$3.35M$3.22M$3.45M$2.48M$2.05M
    R&D$1.66M$2.95M$797,000$2.79M$2.04M$1.78M$1.36M$1.21M$975,000$960,000$773,000$571,000
    SG&A$2.38M$2.12M$1.79M$2.25M$2.45M$2.75M$2.36M$2.14M$2.25M$2.49M$1.71M$1.48M
    Operating Income$-4,033,000$-5,068,000$-2,590,000$-5,038,000$-4,490,000$-4,531,000$-3,712,000$-3,352,000$-3,224,000$-3,450,000$-2,480,000$-2,052,000
    Interest Income$15,000$20,000$25,000$73,000$50,000$99,000$63,000$79,000$70,000$39,000$0$0
    Interest Expense$7,000$4,000$204,000$0$0$0$6,000$5,000$5,000$4,000$1,000$0
    Income Before Tax$-4,117,000$-5,000,000$-3,244,000$-5,778,000$-4,658,000$-4,966,000$-3,099,000$-500,000$898,000$-8,460,000$-9,717,000$-2,193,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$1
    Net Income$-4,117,000$-5,000,000$-3,244,000$-5,778,000$-4,658,000$-4,966,000$-3,099,000$-500,000$898,000$-8,460,000$-9,717,000$-2,193,000
    EBITDA$-3,872,000$-4,759,000$-2,806,000$-5,547,000$-4,452,000$-4,805,000$-2,940,000$-352,000$1.04M$-8,319,000$-9,586,000$-2,081,000
    EBIT$-4,033,000$-4,996,000$-3,040,000$-5,778,000$-4,658,000$-4,966,000$-3,093,000$-495,000$903,000$-8,456,000$-9,716,000$-2,193,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBLG

    News

    FibroBiologics receives Australian patent acceptance for disc treatment

    FibroBiologics, Inc. has announced that IP Australia has accepted its patent application for a "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells." This patent covers methods to generate...

    Investing.com•10/14/26•Bullish

    FibroBiologics receives Australian patent acceptance for disc treatment By Investing.com

    FibroBiologics, Inc. has announced that IP Australia has accepted its patent application for "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells." This patent covers methods for generating...

    Investing.com Canada•10/14/26•Bullish

    FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

    FibroBiologics, Inc. announced that IP Australia has accepted its patent application for a cellular blend designed to regenerate chondrocytes and cartilage cells in degenerated spinal discs. The patent covers methods...

    PR Newswire•10/14/26•Bullish

    FibroBiologics receives Australian patent acceptance for spinal disc treatment

    FibroBiologics, Inc. announced that IP Australia has accepted its patent application for "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells," which covers methods for treating degenerated spinal...

    StreetInsider•10/14/26•Bullish

    FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

    FibroBiologics has announced that IP Australia has accepted its patent application for a cellular blend designed to regenerate chondrocytes and cartilage cells in degenerated spinal discs. This patent protects methods...

    Yahoo Finance•10/14/26•Bullish

    FBLG Valuation and Fair Value

    P/E
    -0.2x
    P/B
    0.8x
    See GNG's fair value

    FBLG Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -660.0%

    FBLG Competitors

    CompanyTicker
    Skye Bioscience, Inc. Common StockSKYE
    Nutriband Inc. WarrantNTRBW
    Predictive Oncology IncPOAI
    Neurosense Therapeutics LtdNRSN
    InMed Pharmaceuticals IncINM
    Co-Diagnostics, Inc. Common StockCODX
    XWELL Inc.XWEL
    Enveric Biosciences IncENVB

    Sector: Healthcare

    FBLG Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    20.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.63
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About FBLG

    Does FBLG pay dividends?

    FibroBiologics, Inc. Common Stock (FBLG) does not currently pay a regular dividend.

    What is FBLG's market cap?

    FibroBiologics, Inc. Common Stock (FBLG) has a market capitalization of $6.73M with a current stock price of $1.00.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In